Frontiers in Neurology
May 6, 2022
Hannah Ford, Clare L. Fraser, Emma J. Solly et al.
28 citations
Hallucinogen persisting perception disorder (HPPD) involves the return of perceptual symptoms after stopping hallucinogens. In a series of 13 patients and a review of 24 case reports, LSD, MDMA, and cannabinoids were commonly used, often together. The most frequent symptoms were visual snow, floaters, palinopsia, photophobia, and nyctalopia. Most ophthalmic and neurologic tests were normal. Two patients fully recovered, one with benzodiazepine treatment and one without; 25% of literature cases fully recovered. The symptoms overlap with Visual Snow Syndrome, suggesting that HPPD may be a secondary cause of VSS and that diagnostic criteria for HPPD should include visual snow, nyctalopia, photophobia, and floaters.
Frontiers in Neurology
June 29, 2023
Benjamin N. Blond, Emmanuelle A. D. Schindler
11 citations
A person with refractory right temporal lobe epilepsy who had an implanted responsive neurostimulation (RNS) system experienced a large increase in typical seizure frequency after ingesting a large dose of psychedelic mushrooms. This is the first reported case with electrographic confirmation of seizures linked to classic psychedelic drug use. The findings indicate that the risk of drug-induced seizures should be considered in the context of the re-emerging clinical use of classic psychedelics, particularly for individuals with a history of epilepsy and depending on drug doses and regimens.
Frontiers in Neurology
June 25, 2025
Rania Abutarboush, Usmah Kawoos, Rita de Gasperi et al.
3 citations
Repetitive low-level blast exposure in male rats chronically reduces serotonin 2A receptor (5-HT2AR) levels in the anterior cerebral cortex, a change detectable from 1 month to at least 12 months after exposure but not at 2 weeks. The hippocampus and amygdala showed variable receptor changes. 5-HT2AR expression correlated differently with certain behavioral measures in blast-exposed versus control rats. These findings suggest a neurochemical basis for blast-induced cognitive and PTSD-related behavioral changes and identify 5-HT2AR as a potential therapeutic target for treating such symptoms in Veterans.